| Clinical parameters | CMR (n = 51) median (range) | Non-CMR (n = 42) median (range) | P values |
|---|---|---|---|
| Age (yr) | 60.7 (28–85) | 59.5 (23–79) | 0.9446 |
| Sex,a female | 20 (39.2) | 15 (35.7) | 0.7287 |
| Weight (kg) | 60.3 (42–84) | 60.7 (45–102) | 0.3965 |
| Sokal risk (low/int./high) | 35/13/2 | 24/11/2 | 0.8688 |
| EUTOS risk (low/high) | 42/3 | 31/2 | 0.9140 |
| CML duration (mo) | 84.8 (22.4–229.4) | 77.3 (13.2–186.3) | 0.6576 |
| Prior IFN-αa | 8 (15.7) | 11 (26.2) | 0.2112 |
| Duration of IM treatment (mo) | 84.3 (22.4–116.6) | 77.1 (12.6–122.4) | 0.5036 |
| Actual daily IM dose (mg/d) | 400 (161.7–400) | 400 (66.7–400) | 0.9098 |
| Median time to CCyR (mo) | |||
| From diagnosis to CCyR | 6.6 (2.5–60.1) | 6.5 (1–103.3) | 0.8728 |
| From IM therapy to CCyR | 5.7 (2–46.5) | 4.8 (0.5–76.7) | 0.5431 |
| Median time to MMR (mo) | |||
| From diagnosis to MMR | 15.8 (4.4–185.6) | 30.5 (4.4–167.8) | 0.0937 |
| From IM therapy to MMR | 15.1 (3.2–76.1) | 19.6 (3.6–93.9) | 0.2429 |
| IM trough concentration (ng/ml) | 981.8 (336.3–2,687.7) | 1151.7 (124.4–2,624.1) | 0.5597 |
| BIM deletiona | 4 (7.8) | 7 (16.6) | 0.1898 |
| Clinical parameters | CMR ( | Non-CMR ( | P values |
|---|---|---|---|
| Age (yr) | 60.7 (28–85) | 59.5 (23–79) | 0.9446 |
| Sex, | 20 (39.2) | 15 (35.7) | 0.7287 |
| Weight (kg) | 60.3 (42–84) | 60.7 (45–102) | 0.3965 |
| Sokal risk (low/int./high) | 35/13/2 | 24/11/2 | 0.8688 |
| EUTOS risk (low/high) | 42/3 | 31/2 | 0.9140 |
| CML duration (mo) | 84.8 (22.4–229.4) | 77.3 (13.2–186.3) | 0.6576 |
| Prior IFN-α | 8 (15.7) | 11 (26.2) | 0.2112 |
| Duration of IM treatment (mo) | 84.3 (22.4–116.6) | 77.1 (12.6–122.4) | 0.5036 |
| Actual daily IM dose (mg/d) | 400 (161.7–400) | 400 (66.7–400) | 0.9098 |
| From diagnosis to CCyR | 6.6 (2.5–60.1) | 6.5 (1–103.3) | 0.8728 |
| From IM therapy to CCyR | 5.7 (2–46.5) | 4.8 (0.5–76.7) | 0.5431 |
| From diagnosis to MMR | 15.8 (4.4–185.6) | 30.5 (4.4–167.8) | 0.0937 |
| From IM therapy to MMR | 15.1 (3.2–76.1) | 19.6 (3.6–93.9) | 0.2429 |
| IM trough concentration (ng/ml) | 981.8 (336.3–2,687.7) | 1151.7 (124.4–2,624.1) | 0.5597 |
| BIM deletion | 4 (7.8) | 7 (16.6) | 0.1898 |
BIM, BCL2L11 gene; CCyR, complete cytogenetic response; EUTOS, European Treatment and Outcome Study; IM, imatinib; int., intermediate; MMR, major molecular response.
Data presented as number (%) of patients.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Please sign in to your personal account to gift article access.
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
Each link will stop working after 30 days or 10 uses. You may create up to 10 links in a 30 day period.
Gift articles remaining: --
As a benefit of your subscription, you can share temporary access to restricted articles.
Each link will stop working after 30 days or 10 uses.
You have reached the limit of 10 links within a 30 day period.
Sharing content requires targeting cookies to be enabled. Please update your cookie preferences to use this feature.